Listen to Dr. Lim discuss the available data on the use of cancer immunotherapies for the care of patients with glioblastoma (GBM).
This activity is intended for oncologists, neurologists, radiologists and surgeons who treat patients with GBM.
The goal of this activity is to discuss the potential impediment of immune privilege, ways to circumvent it in GBM, mechanisms of action of novel therapies, and data from emerging and on-going clinical trials.
Approximate Time to Complete: 30 minutes
Course Available Beginning: Mar. 23, 2017
Developed through a partnership between SITC and Medscape.
Upon completion of this activity, participants will be able to:
- Have increased knowledge regarding the novel ability of different immunotherapeutic treatments to overcome the immune specialization of GBM
- Have increased knowledge regarding the available data on the use of cancer immunotherapies being studied in the management of GBM